Multiple-dose, Double-blind, Double-dummy Study to Compare the Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism

Trial Profile

Multiple-dose, Double-blind, Double-dummy Study to Compare the Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2017

At a glance

  • Drugs Etelcalcetide (Primary) ; Cinacalcet
  • Indications Secondary hyperparathyroidism
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 01 Nov 2017 Planned End Date changed from 11 Apr 2019 to 19 Jul 2019.
    • 01 Nov 2017 Planned primary completion date changed from 11 Apr 2019 to 19 Jul 2019.
    • 01 Nov 2017 Planned initiation date changed from 31 Jan 2018 to 1 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top